Dyadic says C1 platform and protein products are gaining momentum

Dyadic Applied BioSolutions says its C1 protein platform is drawing renewed interest as global health agencies track a Bundibugyo Ebola outbreak, while the company also expands commercial protein and enzyme products. The updates come as Dyadic reports stronger first-quarter revenue, a narrower loss and cash runway into 2027.

Why it matters: - Dyadic Applied BioSolutions is trying to prove its business is not dependent on a single clinical milestone. - The company is positioning its C1 and Dapibus platforms as tools for faster protein and enzyme development across health, food and industrial markets. - Dyadic estimates the addressable market for its platforms at about $25 billion.

What happened: - On June 15, 2026, Dyadic highlighted rising interest in its C1 protein production platform as the Bundibugyo Ebola virus outbreak kept global health agencies focused on preparedness. - Dyadic says C1 can move from a viral gene sequence to a purified recombinant antigen in about 15 days. - The company contrasts that timeline with the four-to-six months often associated with standard CHO-cell manufacturing. - Dyadic is working with research groups including Scripps Research on vaccine and antibody candidates. - Dyadic Applied BioSolutions was formerly known as Dyadic International Inc. and is based in Jupiter, Florida.

The details: - The C1 platform is built on the fungus Thermothelomyces heterothallica. - Dyadic said its earlier DYAI-100 study showed C1-produced antigens were generally safe and well tolerated in humans. - Over the past year, Dyadic launched six animal-free protein products across life sciences, food and nutrition, and bioindustrial markets. - The product rollout includes a planned 2026 non-animal dairy enzyme with Inzymes ApS. - Dyadic also announced a first product with Fermbox Bio, a distribution deal with IBT Bioservices, and recombinant human albumin through Proliant Health & Biologicals. - First-quarter 2026 revenue rose 182% year over year to about $1.11 million. - First-quarter results beat analyst estimates. - Net loss narrowed to about $1.95 million, or $0.054 per share, in the first quarter. - Full-year 2025 revenue was $3.09 million, down about 11.6% from the prior year. - Full-year 2025 loss widened. - Dyadic has said its cash runway extends into 2027.

Between the lines: - Dyadic is trying to shift from a research-driven model to a revenue-driven one. - The company’s pitch depends on whether faster protein development can win adoption in a market that tends to favor established manufacturing methods. - The company’s commercial momentum may matter as much as its scientific platform if investors want evidence of durable growth.

What's next: - Investors will be watching whether C1-related interest turns into more partnerships, product launches or clinical use through the rest of 2026. - The key test is whether Dyadic can convert platform attention and early commercial deals into sustained revenue growth. - Forward-looking statements in the company update remain subject to risk and uncertainty.